UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2015
Immune Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Florida | 000-54933 | 59-3226705 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| or incorporation) | File Number) | Identification Number) |
| | | |
| 37 North Orange Avenue, Suite 607, Orlando, Florida | 32801 |
| (Address of principal executive offices) | (Zip Code) |
(888) 613 - 8802
(Registrant’s telephone number, including area code)
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
ClearTrust, LLC is our new transfer agent and shareholder provider. ClearTrust, LLC acquired all issuer accounts of our former transfer agent, Guardian Registrar & Transfer, Inc. As a result, effective January 21, 2015, ClearTrust, LLC became our transfer agent. All of the directly held shares of common stock of our shareholders were transferred from Guardian Registrar & Transfer, Inc. to ClearTrust, LLC’s platform. A copy of the letter to our shareholders regarding this change is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| | Exhibit No. | Description |
| | | |
| | 99.1 | Shareholder Letter Regarding Transfer Agent Change |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | Immune Therapeutics, Inc. |
| | | |
| | | By:/s/ Noreen Griffin |
| | | Noreen Griffin, Chief Executive Officer |
Date: January 26, 2015
EXHIBIT INDEX
| | Exhibit No. | Description |
| | | |
| | 99.1 | Shareholder Letter Regarding Transfer Agent Change |
